Archive
Home / Media Centre / Archive
Here you can find the archive of all Press Releases prior to 2022
Filter by date:
Showing 1107 press releases before 2022
-
Q1 2017 Results
-
Tagrisso receives full approval in the EU
-
AstraZeneca marks a key milestone with the ‘topping out’ of new global R&D centre and HQ in Cambridge, UK
-
Tagrisso (osimertinib) receives US FDA full approval
-
AstraZeneca’s potential medicine for neuromyelitis optica spectrum disorder receives orphan designation in Europe
-
Astrazeneca to share its robust early science in oncology with the medical community at AACR 2017
-
Tagrisso approved in China as first-in-class treatment for EGFR T790M mutation-positive metastatic non-small cell lung cancer
-
AstraZeneca’s CVD-REAL study shows SGLT-2 inhibitors significantly reduced death and hospitalisations for heart failure versus other type-2 diabetes medicines
-
AstraZeneca and Circassia enter strategic collaboration in respiratory disease
-
AstraZeneca receives Complete Response Letter from US FDA for ZS-9 (sodium zirconium cyclosilicate) for hyperkalaemia
Latest articles and press releases
All of our latest press releases and articles are available to explore
